American Heart Journal
Volume 156, Issue 1 , Pages 1-3 , July 2008

Risk factors and stroke risk stratification for atrial fibrillation: Limitations and new possibilities

  • Gregory Y.H. Lip, MD, FRCP

      Affiliations

    • Corresponding Author InformationReprint requests: Gregory Y.H. Lip, MD, FRCP, University Department of Medicine, City Hospital, Birmingham, England.

Received 18 February 2008 ,Accepted 29 February 2008.

References 

  1. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6:981–993
  2. Hughes M, Lip GYH. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemostat. 2008;
  3. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69:546–554
  4. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006;27:3018–3026
  5. Lip GYH. Coronary artery disease and ischaemic stroke in atrial fibrillation. Chest. 2007;132:8–10
  6. Conway DS, Lip GY. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol. 2004;93(11):1422–1425
  7. Gage BF, Walraven CV, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287–2292
  8. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255–1262
  9. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752–759
  10. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified. Stroke. 2007;38:
  11. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51:810–815
  12. Reitbrock S, Heeley E, Plumb J, et al. Chronic atrial fibrillation: incidence, prevalence and prediction of stroke using the Congestive heart failure, Hypertension, Age > 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156:57–64
  13. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049–1056
  14. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;[in press]
  15. Lip GY, Lane D, Van Walraven C, et al. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006;37:2294–2300
  16. Nozawa T, Inoue H, Hirai T, et al. d-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol. 2006;109:59–65

PII: S0002-8703(08)00195-6

doi: 10.1016/j.ahj.2008.02.020

American Heart Journal
Volume 156, Issue 1 , Pages 1-3 , July 2008

Article Tools